Dr. Raymond Roos, Editor-in-Chief, serves on the Scientific Advisory Board of Revalesio Corporation and a Data and Safety Monitoring Board for a clinical trial of a Mallinckrodt Pharmaceuticals product, has received consulting fees from M-T Pharmacy and Best Doctors and holds shares in Amgen, Merck, Ionis, and GE. Financial disclosures for all others who contribute to educational content are provided at the beginning of each article to which they contribute. Financial disclosures of Associate Editors are also shown here. MedLink Corporation does not accept financial support from commercial interests. None of its personnel have financial relationships with commercial interests.